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Abstract
Introduction: As prevalence of undiagnosed HIV declines, it is unclear whether testing programmes will be cost-effective. To
guide their HIV testing programmes, countries require appropriate metrics that can be measured. The cost-per-diagnosis is
potentially a useful metric.
Methods: We simulated a series of setting-scenarios for adult HIV epidemics and ART programmes typical of settings in
southern Africa using an individual-based model and projected forward from 2018 under two policies: (i) a minimum
package of “core” testing (i.e. testing in pregnant women, for diagnosis of symptoms, in sex workers, and in men coming
forward for circumcision) is conducted, and (ii) core-testing as above plus additional testing beyond this (“additional-
testing”), for which we specify different rates of testing and various degrees to which those with HIV are more likely to
test than those without HIV. We also considered a plausible range of unit test costs. The aim was to assess the rela-
tionship between cost-per-diagnosis and the incremental cost-effectiveness ratio (ICER) of the additional-testing policy.
The discount rate used in the base case was 3% per annum (costs in 2018 U.S. dollars).
Results: There was a strong graded relationship between the cost-per-diagnosis and the ICER. Overall, the ICER was below
$500 per-DALY-averted (the cost-effectiveness threshold used in primary analysis) so long as the cost-per-diagnosis was below
$315. This threshold cost-per-diagnosis was similar according to epidemic and programmatic features including the prevalence
of undiagnosed HIV, the HIV incidence and a measure of HIV programme quality (the proportion of HIV diagnosed people
having a viral load <1000 copies/mL). However, restricting to women, additional-testing did not appear cost-effective even at a
cost-per-diagnosis of below $50, while restricting to men additional-testing was cost-effective up to a cost-per-diagnosis of
$585. The threshold cost per diagnosis for testing in men to be cost-effective fell to $256 when the cost-effectiveness thresh-
old was $300 instead of $500, and to $81 when considering a discount rate of 10% per annum.
Conclusions: For testing programmes in low-income settings in southern African there is an extremely strong relationship
between the cost-per-diagnosis and the cost-per-DALY averted, indicating that the cost-per-diagnosis can be used to monitor
the cost-effectiveness of testing programmes.
Keywords: testing; HIV; cost-effectiveness; modelling; health systems
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1 | INTRODUCTION
A key strategy in global efforts to reduce incidence of HIV
infection is to aim for high levels of diagnosis of HIV-positive
individuals and to help people with diagnosed HIV to initiate
and remain on ART with high adherence [1–3]. Countries are
being encouraged to set up large-scale testing programmes to
attain the target of at least 90% of people living with HIV
(PLHIV) being diagnosed by 2020 and at least 95% by 2025.
However, as the prevalence of undiagnosed HIV declines over
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time, the proportion of HIV tests that result in diagnosis of an
HIV-infected person will also decline. Thus, the cost-effective-
ness of HIV testing strategies becomes increasingly uncertain.
Various HIV testing approaches have been used and they dif-
fer in the extent to which tests are more likely to be con-
ducted in PLHIV than in those without, and in their cost per
test conducted [4–6]. For example, testing programmes based
on partner notification might have a high cost per HIV test
but also a high test-positive rate (sometimes referred to as
“yield”). Some testing approaches that are currently imple-
mented may not be cost-effective. Countries require appropri-
ate metrics that can be feasibly measured to guide their HIV
testing programmes. A key metric of potential interest is the
cost-per-diagnosis (i.e. diagnosis in persons never previously
having had a positive test). However, it is not intuitively clear
what is the maximum cost-per-diagnosis at which HIV testing
in low-income countries in southern Africa remains cost-effec-
tive. Nor is it clear whether the value of this threshold
depends substantially on epidemic or programmatic features.
In this paper, we make use of simulation modelling of HIV epi-
demics and testing programmes to consider these questions
to provide guidance to HIV testing programmes.
2 | METHODS
We used an individual-based stochastic simulation model of
HIV transmission, progression and the effect of ART in adult
populations in southern Africa, which has been described pre-
viously [7,8] and is detailed in supplementary materials. Each
time the model is run it simulates data in three-monthly time
steps on whether the person has an ongoing primary condom-
less sex partner, the number of other condomless sex part-
ners, HIV testing, HIV acquisition risk and, in people living
with HIV, viral load, CD4 count, use of specific ART drugs,
adherence, resistance and risk of HIV-related death. In addi-
tion to the health benefit to the individual of being diagnosed
earlier, the model provides a means by which the effects of
testing on increasing the proportion of HIV-positive people
who are on ART translate into greater health for the individ-
ual and lower onward transmission, and of estimating the
overall number of disability adjusted life years (DALYs)
averted in the adult population as a whole.
We initially based the modelled scenarios on data from
Malawi but varied parameter values (i.e. we independently
sampled randomly from the distributions shown in Table S9,
section 6 of the Supplementary Appendix) for each model run
in order to generate a range of “setting-scenarios.” These
reflect the range of situations in low and low-middle income
settings in southern Africa in terms of epidemic, HIV testing
and ART programme characteristics. We generated 1000 such
setting-scenarios in which we track an adult population initially
of approximately 20,000 people (with population growth
accounted for) and then scaled up the outputs to an adult
population the size of Malawi (approximately 10 million). The
only constraints beyond those arising from the parameter dis-
tributions are that we excluded setting scenarios outside the
following ranges: HIV prevalence in 2017 3% to 35%; relative
prevalence in 25 to 35 year old women >1.5 times greater
than that in 25- to 35-year-old men; probability of an HIV test
when HIV-related symptoms are present >0.30; number of
sex workers who have condomless sex (in our model a sex
worker is defined as a woman having had five or more
condomless sex partners in any one three-month period in the
past year) 2,500 to 200,000. The characteristics of the 1000
setting-scenarios in 2017 are presented in Table 1, along with
examples of observed data. We consider it plausible that each
of the setting-scenarios represent the real situation in certain
sub-settings in sub-Saharan Africa defined by geography and
demographics.
For each setting-scenario, we used the model to make pro-
jections for 50 years from 2018 to 2068 under two policies.
Under both policies, “core” testing (hereafter referred to as
core-testing) is assumed to be offered; that is testing in preg-
nant women (one per pregnancy, although many countries aim
for two or three tests per pregnancy), for diagnosis of symp-
toms, every six months in sex workers who have condomless
sex (although this is not currently happening in many settings),
and in men coming forward for circumcision. In the reference
policy, there is no additional HIV testing beyond core-testing
(so in some setting-scenarios this means less testing than pre-
2018), while in the “additional testing” policy (policy hereafter
referred to as additional-testing) there is additional testing.
The characteristics of the additional testing differed for each
setting-scenario; we selected at random a rate of testing per
three-month period and a relative probability of HIV-positive
people being tested compared with HIV-negative people
(which is possible as the true status of a “person” in the model
is known). This random selection was from relative rates of
testing of 0.1, 0.333, 1, 3, 10 and 30 times the existing testing
rate in 2017, and relative probabilities of HIV-positive people
being tested ranging from 1, to 10, 100 and 1000 times the
probability of HIV-negative people being tested. This was done
in order to generate across setting-scenarios various different
proportions of tests which result in diagnosis. We chose core-
testing as the reference policy rather than the current testing
because we did not want to make any implicit assumption
about cost-effectiveness of current testing beyond core-test-
ing. We only included setting scenarios in which the number
of additional new HIV diagnoses per year is at least 5000. In
two-thirds of the 1000 model runs (setting-scenarios), we
restricted additional-testing to men or women only, while in
the remainder additional-testing was in both sexes. We
assume that the criteria for ART initiation followed those from
Malawi up to 2017 and that all people are eligible for ART at
diagnosis from 2017 and that viral load monitoring is used
from 2017. For each of the setting scenarios we ran 10 repli-
cations of each policy to reduce influence of stochastic effects,
which was adjudged to be sufficient based on the relative
smoothness of the derived relationship between cost-per-diag-
nosis and the median ICER (Table 3).
We describe the effect of the additional-testing policy on
intermediate measures including the mean proportion of peo-
ple testing in the past year, the proportion of HIV tests result-
ing in a diagnosis, the cost of HIV testing per new diagnosis
(hereafter referred to as cost-per-diagnosis), and the percent-
age of HIV-positive people diagnosed over the five-year per-
iod from 2018 to 2023. The cost-per-new-diagnosis was
based on the assumed testing cost of $3.70 (Clinton Health
Access Initiative, personal communication, which is consistent
with previous costs in the region at high-volume facilities [9]),
with a total testing cost of $25 for people diagnosed positive,
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Table 1. Characteristics of the 1000 HIV epidemic/ART programme setting-scenarios in 2017 (median; 90% range, reflecting vari-
ability across setting-scenarios), in context of country the size of Malawi (adult population age 15 to 65 approx. 10 million)
Median (90% range) across setting-
scenarios (n = 1000) Examples of observed data
HIV prevalence (age 15 to 49) 8.2% (4.7% to 17.4%) Zimbabwe DHS (2015) 14%, Tanzania (2011) 5%, Uganda
(2011) 9%, Lesotho (2014)25% [22].
Relative HIV prevalence by age and
sex (relative to men age 25 to 34)
Women Men Zimbabwe DHS 2015 men age 15 to 24 0.29, age 35 to
44 2.18, age 45 to 54 2.52; women age 15 to 24 0.69,
age 25 to 34 1.82, age 35 to 45 2.88 [22]15 to 24 0.52 (0.28 to 0.77) 0.22 (0.12 to 0.33)
25 to 34 1.88 (1.56 to 2.38) 1.00
35 to 44 3.11 (2.37 to 4.41) 2.15 (1.67 to 3.01)
45 to 54 2.62 (1.85 to 4.16) 1.91 (1.37 to 2.90)
55 to 64 1.12 (0.69 to 1.88) 1.12 (0.73 to 1.69)
Prevalence of undiagnosed HIV
Overall 1.5% (0.7% to 3.5%) Malawi 2.9%, Zimbabwe 3.8%, Zambia 4.0 (PHIA 2016) [23]
Rwanda ~ 0.3% (Nsanzimana [24]) (Survey estimates could
be over-estimates due to undisclosed diagnosed HIV;
Kim et al [25])
Women 1.2% (0.5% to 2.9%)
Men 1.9% (0.8% to 4.3%)
Time since infection among undiagnosed population
Women No data known to be available
<1 year 38% (25% to 51%)
1 to 5 years 41% (32% to 52%)
≥5 years 20% (11% to 33%)
Men
<1 year 24% (15% to 34%)
1 to 5 years 50% (41% to 57%)
≥5 years 26% (14% to 40%)
HIV incidence (age 15 to 49) per
100 person years
0.64 (0.25 to 1.52) MPHIA (0.37%), ZAMPHIA (0.66%), ZIMPHIA (0.45%) [23],
Swaziland 2.4% (Justman [26]), Mbongolwane and Eshowe,
KZN 1.2% (Huerga [27])
Number of HIV tests in year
All adultsa 2,641,000 (1,397,000 to 3,710,000) Zimbabwe 2.1 m (2016) [28], Malawi 2.2 m (2015) [29]
Women overalla 1,787,000 (1,004,000 to 2,455,000)
Men overalla 835,000 (363,000 to 1,298,000)
ANC 650,000 (317,000 to 1,115,000)
FSW 32,000 (9,000 to 93,000)
Symptomatic 232,000 (221,000 to 247,000)
Men for VMMC 72,000 (66,000 to 76,000)
Testing beyond core-testingb
All adults 1,602,000 (438,000 to 2,652,000)
Women 961,000 (271,000 to 1,552,000)
Men 649,000 (165,000 to 1,115,000)
Percentage of tests resulting in HIV diagnosis
All adultsa 2.9% (1.2% to 7.7%) Estimates are susceptible to bias due to re-diagnosis of
people who do not report previous diagnosis. 6% to 55%
depending on group (Sharma et al [5]).
Women overalla 2.6% (1.0% to 7.7%)
Men overalla 3.5% (1.4% to 9.1%)
ANC 2.8% (0.8% to 22.9%)
FSW 33.7% (10.8% to 49.2%)
Symptomatic 7.7% (3.3% to 16.6%)
Men for VMMC 1.3% (0.4% to 3.6%)
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Table 1. (Continued)
Median (90% range) across setting-
scenarios (n = 1000) Examples of observed data
Testing beyond core-testingb
All adults 1.7% (0.8% to 4.1%)
Women 1.4% (0.6% to 3.6%)
Men 2.2% (1.0% to 5.3%)
Cost of testing per new HIV diagnosisc
All adultsa $159 ($73 to $357) Few estimates reported. Estimates are susceptible to bias
described above. >$500 (Bogart 2017; fisher folk
Uganda [30]). $36 (Rutstein 2014; partner notification
Malawi [31]); $157-$189 in 2010 (Grabbe; mobile and
stand-alone HIV counselling and testing approaches in
Kenya [32]); $25-$76 (Maheswaran; facility based testing
in Malawi [33]).
Women overalla $188 ($81 to $452)
Men overalla $133 ($63 to $314)
ANC $233 ($95 to $650)
FSW $30 ($27 to $48)
Symptomatic $71 ($42 to $157)
Men for VMMC $139 ($112 to $161)
Testing beyond core-testingb
All adults $253 ($115 to $540))
Women $336 ($135 to $792)
Men $214 ($101 to $472)
Proportion tested Zimbabwe DHS 2015 49% women, 36% men (age 15 to 49).
Namibia DHS 2013 49% women, 38% men (age 15 to 49).
Nigeria DHS 2013 10% women, 10% men [22]
Overall in past year women
age 15 to 49
37% (22% to 48%)
Overall in past year males
age 15 to 49
16% (7% to 25%)
Among those symptomatic with
HIV symptomsd 90% (46% to 93%)
In pregnancy 92% (89% to 93%)
FSW (proportion tested in each
3 month period)
25% (17% to 41%)
Of HIV-positive people, proportion diagnosed
Men 73% (59% to 82%) MPHIA 2016 Malawi (73%; 76% in women, 67% in men),
ZAMPHIA 2016 Zambia (67%), ZIMPHIA 2016 Zimbabwe
(74%) [23], Huerga (75%) [27], Maman (77%) [34], Gaolathe
(78%, higher in women than men) [35]. (Survey estimates
likely to be over-estimates due to undisclosed diagnosed
HIV; Kim et al [25])
Women 89% (82% to 93%)
Proportion of diagnosed
people on ART
83% (66% to 92%) Zimbabwe 87% (ZIMPHIA), Malawi 89% (MPHIA),
Zambia 85% (ZAMPHIA) [23], Botswana 85% (Gaolathe) [35].
Proportion of people on
ART with VL <1000 cps/mL
88% (84% to 92%) World Bank South Africa (60% to 88% over districts),
ZAMPHIA (89%), MPHIA (91%), ZIMPHIA (87%) [22],
Maman (91%) [34], Huerga (90%) [27], Brown (90%)36,
Botswana 94% (Gaolathe; among citizens of Botswana) [35]
ANC, ante-natal clinic; FSW, female sex worker; VMMC, voluntary medical male circumcision.
aThis relates to all testing, not only core-testing; btesting apart from in FSW, symptomatic, ANC, VMMC; cif cost per test = $3.70; dsymptoms of a
WHO stage 3 or 4 condition.
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due to the need for confirmatory testing and appropriate
counselling. Costs are in 2018 US dollars. A five-year period
was chosen to allow a sufficient time to fully characterize the
additional-testing policy. The testing costs included in the anal-
ysis are conceived of as the fully loaded costs of a test being
done, including any demand generation, supply chain, fuel,
wastage, human resources in administering the test as well as
the kit itself. The annual cost of the first-line regimen of efa-
virenz, lamivudine, tenofovir is $100 per person per year (with
dolutegravir replacing efavirenz by 2019, with a total regimen
cost of $75 per person year), programme costs for clinic visits,
not including drug, viral load, or CD4 count tests, are $20 per
three months [10,11] with an assumed reduction to $10 per
three months when viral load is <1000 copies/mL [8]. Disabil-
ity weights to calculate DALYs were derived from a compre-
hensive study [12].
In order to generate a range of situations with regard to
cost per unit test we considered a range of plausible unit
costs of HIV tests in addition to the baseline cost of $3.70:
$1, $2, $5, $7, $10, $12 and increments of $3 up to $36. The
higher unit costs are conceived of as relating to situations in
which there are substantial costs in identifying and reaching
people to target for testing (e.g. contact tracing). This was
applied for all HIV tests, not just the additional tests and
includes all costs relating to performing a test, not just the
cost for the kit itself. A total of 16,000 setting-scenario/test
unit cost combinations were therefore considered (16 differ-
ent unit costs for each of 1000 setting-scenarios). For each of
these we calculate the cost-per-diagnosis resulting from the
additional-testing as the ratio between the cumulative (undis-
counted) cost of additional-testing and the number of diag-
noses due to additional-testing, averaged over the five years
2018 to 2023. We then assessed the relationship between
the cost-per-diagnosis and the incremental cost-effectiveness
ratio (ICER) for additional-testing over core-testing alone, with
the ICER calculated over the 50 year time horizon. The ICER
takes account of all costs, including downstream costs (and
potential savings in downstream costs) resulting from the test-
ing and diagnosis. Unlike the cost-per-diagnosis, the cost-per-
DALY-averted cannot be readily measured by programmes
and used directly to monitor them.
We take a healthcare perspective for our cost-effectiveness
analysis. The health-financing environment for HIV in Malawi
and other countries is complex, with international funding ini-
tiatives channelled particularly to support HIV testing. In each
setting-scenario/unit test cost combination, additional-testing
was deemed to be cost-effective if the ICER was below $500
per DALY averted or if there was a saving in cost with the
additional-testing policy and DALYs were averted. This use of
the cost-effectiveness threshold reflects the health foregone
(opportunity costs) due to resources committed to HIV testing
consequentially being unavailable to provide other HIV inter-
ventions (so that $500 reflects the cost-per-DALY-averted of
these foregone activities) [13,14]. Severe constraints on over-
all healthcare spending in low-income countries in the region,
and Malawi [15] in particular, mean that this cost-effective-
ness threshold is only likely to be relevant for resource alloca-
tion within the HIV programme which is overwhelmingly
reliant on overseas aid [16]. The Ministry of Health in Malawi
also has to support the delivery of other (non-HIV) healthcare
interventions that generate health gains at less than this
amount remain, for example diagnosis and treatment for
hypertension. The cost-effectiveness threshold reflecting the
resource allocation decisions it faces is therefore likely to be
much lower. This implies more health could be gained using
some HIV funding for other pressing healthcare needs. Where
delivery of HIV interventions draws upon resources that
would otherwise be used for other health activities such as
the use of staff resources a lower threshold would probably
be required, and we use $300 and $150 in sensitivity analy-
ses. We follow convention and use a discount rate of 3% per
annum for both costs and outcomes in the main analysis [17],
although real rates of interest faced by governments in the
region are often much higher than this. Therefore, we also
consider discount rates of 0% and 10% in sensitivity analyses.
All costs are in U. S dollars.
We fitted a logistic curve for the relationship over setting-
scenarios between the cost-per-diagnosis and whether the
ICER was below $500 or not (the binary outcome variable), in
order to derive the median (and 80% centile) cost of testing
per new HIV diagnosis across setting scenario/unit test cost
combinations.
Finally, since our core-testing comparison includes six
monthly testing in sex workers, we repeated the above-
described process but instead of comparing core-testing-only
with core-testing-plus-additional-testing we compared core-
testing with core-testing minus targeted-testing in sex work-
ers. This was to assess our assumption that testing in sex
workers is cost-effective.
Ethical approval was not relevant for this study as it does
not involve human subjects.
3 | RESULTS
The characteristics of the 1000 setting-scenarios in 2017,
before the introduction of our specified testing policies of
core-testing and core-testing plus additional-testing, are pre-
sented in Table 1. Table 2 shows the undiscounted median
and 90% range over setting-scenarios of the effect of the
additional-testing policy on a range of outputs over the first
five years from initiation of the policy (i.e. 2018 to 2023). For
women, results are based only on setting-scenarios in which
there is additional-testing in women, irrespective of whether
or not there is also additional-testing in men. The same applies
to men. The number of additional tests over and above core-
testing of 496,000 (27,000 to 4,211,000) in women and
371,000 (25,000 to 4,295,000) in men represents an 8%
(90% range +0.4% to 67%) higher proportion of women
tested per year, and 6% (90% range +0.4% to 75%) higher
proportion of men tested per year respectively. With the pol-
icy of additional-testing, the proportion of people with HIV
who are diagnosed (average 2018 to 2023) is a median of 7%
higher in women and 21% in men. The median cost-per-diag-
nosis of additional-testing was $399 (90% range $25 to
$7,187) in women and $288 ($21 to $4,975) in men. We also
calculated the undiscounted cost-per-diagnosis over the full
50 years from 2018 to 2068 and the median cost was 1.24
times greater than the cost over the first five years.
In Table 3 and Figure 1, we present the median ICER
(cost-per-DALY averted) across setting-scenario/test unit
cost combinations according to the cost-per-diagnosis. We
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also show the proportion of such combinations in which addi-
tional-testing is cost-effective, based on a cost-effectiveness
threshold of $500 (also shown in Figure 2). Considering addi-
tional-testing overall (additional-testing in both men and
women, in women alone, or in men alone), there is a strong
graded relationship between the cost-per-diagnosis and the
ICER. In around 50% of combinations additional-testing is
cost effective when the cost-per-diagnosis is $300 to $400
per new diagnosis ($315 based on fitting a logistic curve;
80% centile $17).
Figure 3 shows the median (80% centile) across setting
scenario/unit test cost combinations for the maximum
cost-per-diagnosis that allowed additional-testing to still be
cost-effective according to various factors. Importantly, this
threshold cost-per-diagnosis did not vary substantially accord-
ing to several epidemic and programmatic features in 2017,
namely the proportion of diagnosed people with viral suppres-
sion (a measure of the overall quality of on ART programme),
proportion of people with symptoms due to HIV who are
tested as a result, the prevalence of undiagnosed HIV, and
HIV incidence in 2017. It also does not vary substantially
according to the test unit cost. This result suggests that the
relationship we describe is likely to hold across the diverse
settings in southern Africa shown in Table 1.
When we restricted additional-testing to women only, there
remained a strong relationship between the cost-per-diagnosis
and the ICER, but the median ICER was above the $500
threshold even in the lowest category of cost-per-diagnosis
and the proportion of setting-scenario/test-cost combinations
in which additional-testing was cost-effective was always
below 50%. This implies that additional-testing was not cost-
effective regardless of the cost-per-diagnosis (Table 3(b) and
Figure 3). In contrast, additional-testing in men only was cost-
effective up to a cost-per-diagnosis of $585 (median; 80%
Table 2. Effect of additional-testing on number of tests, testing
rates and proportion diagnosed 2018 to 2023 (median & 90%
range across 1000 setting-scenarios of the mean value over
2018 to 2023, reflecting variability across setting scenarios)
Effect of additional-testinga
Number of HIV tests/year
Womenb +496,000 (+27,000 to +4,211,000)
Menc +371,000 (+25,000 to +4,295,000)
Number of new diagnoses per year
Womenb +20,370 (+7,200 to +49,470)
Menc +28,890 (+8,980 to +67,210)
Proportion tested in the past year (age 15 to 49)
Womenb +8% (+0.4% to +67%)
Menc +6% (+0.4% to +75%)
Of HIV-positive people, proportion diagnosedd
Womenb +7% (+2% to +12%)
Menc +21% (+5% to +33%)
Cost-per-diagnosis with additional-testinge
Womenb $399 ($25 to $7,187)
Menc $288 ($21 to $4,975)
aWithin-scenario (model run) difference; bacross 667 setting-scenarios
in which additional-testing is done in women and men or in women
only; cacross 667 setting-scenarios in which additional-testing is done
in women and men or in men only; dThe effect of additional-testing is
for the proportion of setting scenarios in which the proportion diag-
nosed is >90% to increase from 0% to 65% in men, and from 29% to
94% in women; eover 10,672 (=667 9 16) setting-scenario/test unit
cost combinations.
Table 3. Cost-effectiveness of additional-testing beyond core
testing and median incremental cost effectiveness ratio (ICER;
cost-per-DALY averted) according to Cost-per-diagnosis
Cost-per-diagnosis
(2018 to 2023)a
Percent of setting-scenarios
in which additional-testing is
cost effectiveb
Median
ICER
(a) overall (additional-testing in both men and women, in women
alone, or in men alone)
<$50 77% (1701/2203) $287
$50 to $100 75% (1062/1411) $316
$100 to $200 71% (1612/2283) $354
$200 to $300 62% (1159/1872) $423
$300 to $400 46% (481/1053) $529
$400 to $500 30% (218/734) $635
$500 to $600 20% (125/618) $737
$600 to $700 13% (60/454) $845
$700 to $1000 9% (81/937) $1014
>$1000 1% (35/4435) $3069
(b) additional-testing in women only
<$50 43% (321/741) $541
$50 to $100 35% (163/454) $602
$100 to $200 33% (246/748) $661
$200 to $300 25% (154/619) $751
$300 to $400 10% (32/333) $1049
$400 to $500 5% (13/238) $1173
$500 to $600 5% (10/204) $1282
$600 to $700 3% (5/148) $1403
$700 to $1000 1% (2/311) $1710
>$1000 to $1500 0% (0/1532) $4871
(c) additional-testing in men only
<$50 94% (742/791) $189
$50 to $100 95% (462/487) $215
$100 to $200 91% (743/814) $243
$200 to $300 89% (581/652) $288
$300 to $400 78% (260/333) $372
$400 to $500 58% (135/232) $463
$500 to $600 44% (84/193) $542
$600 to $700 29% (40/140) $623
$700 to $1000 21% (66/308) $704
>$1000 to $1500 2% (34/1378) $1914
Considering 16,000 setting-scenario/test unit cost combinations
(1000 setting-scenarios 9 16 different unit costs for testing), 5344
(334 9 16) in which additional-testing in both men and women is
introduced; 5328 (333 9 16) each in which it is only introduced in
women; 5328 (333 9 16) each in which it is only introduced in men.
aNot discounted; busing $500/DALY cost effectiveness threshold (This
is to assess for each setting scenario test cost combination whether
additional testing is cost effective).
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percentile $312). Again, there remained a strong relationship
between the cost per new diagnosis and the ICER.
The maximum cost-per-diagnosis for additional-testing to
remain cost-effective fell to $256 (median; 80% centile $46)
when the cost-effectiveness threshold was set to $300 per
DALY averted; with a cost-effectiveness threshold of $150,
additional-testing in men was not cost-effective. When consid-
ering a discount rate of 10% per annum or a shorter time
horizon of 20 years for testing, the maximum cost-per-diagno-
sis for additional-testing in men to remain cost effective was
below $100 (median). In sensitivity analyses in which we used
a 0% discount rate instead of 3%, the median for the maxi-
mum cost-per-diagnosis for testing in men was $821.
Lastly, in our comparison of core-testing with core-testing-
minus-targeted-testing-in-sex workers, we found mean incre-
mental cost-effectiveness ratio which ranged from $115 per
DALY averted, if the unit cost of testing is $1, to $249, if the
unit cost of testing is $36, suggesting that six monthly testing
in sex workers is indeed cost-effective.
4 | DISCUSSION
Countries require appropriate metrics to assess their HIV
testing programmes that can be measured. Our analysis con-
firms that the cost-per-diagnosis is a key metric that is
strongly predictive of the overall cost-effectiveness of an HIV
testing programme. We found that HIV testing programmes
increasing testing in men in low-income settings in southern
Africa are on average cost-effective if they cost below $585
per new diagnosis. If testing due to symptoms, in pregnancy
and in female sex workers having condomless sex (100% test-
ing every six months) is in place, testing women as part of fur-
ther population testing programmes is generally unlikely to be
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cost-effective. In reality, programmes providing regular testing
for sex workers are not as widespread as recommended. If
such a testing programme in sex workers is not in place then
our results indicate such programmes should be introduced.
Our estimates for the cost-per-diagnosis did not vary substan-
tially according to epidemiologic and programmatic character-
istics and so appear to be generalizable to lower income
countries in southern Africa, and likely elsewhere in sub-
Saharan Africa. This is a measure that is increasingly being
reported by studies [9,18–21].
In addition to $500, we also considered a cost-effectiveness
threshold of $300, which recognizes that HIV programmes
can draw resources from other healthcare areas. A threshold
of $300 is still high from an overall perspective of healthcare
provision in Malawi and this suggests that new HIV diagnoses
in men need to be achieved at an average cost below $256
(median over setting scenario/unit test cost combinations).
With a cost-effectiveness threshold of $150, which is closer
to that which applies in Malawi for overall healthcare provi-
sion [15], additional-testing was not cost-effective. Since we
present the relationship between the cost-per-diagnosis and
the ICER, country programmes can apply other cost-effective-
ness thresholds and may have evidence on opportunity costs
in their particular setting. We calculated the cost-per-
diagnosis over the first five years (2018 to 2023) but this can
change over the subsequent 45 years of the total projection;
over the full 50 years this was a median of 1.24 times
greater than the cost over the first five years. For this reason
it is conceivable that short-term testing programmes (e.g. last-
ing 5 years and stopping in 2023) in men that cost somewhat
more than $585 per newly diagnosed man may nevertheless
be cost-effective.
Implementation of our results requires that, besides being
able to estimate the full cost of testing, programmes can also
reliably estimate the number of new HIV diagnoses in a given
period (i.e. without inclusion of people who are being re-diag-
nosed having earlier been tested positive). Testing pro-
grammes rely on self-report to separate positive tests done in
people who have previously received an HIV diagnosis from
those done in people who have never been diagnosed. In
some cases an individual may not wish to disclose a previous
positive test, which makes this information challenging to col-
lect reliably. When estimating the number of new diagnoses
that a programme makes, adjustment will have to be made to
account for the fact that a proportion of apparent new diag-
noses are in fact not, otherwise cost-effectiveness will be
over-estimated. That adjustment factor might be informed by
data on the ratio of the increase over a period of time in the
0 100 200 300 400 500 600
Maximum cost-per-diagnosis  (US $)
median over seng scenario / unit test cost combinaons
80% cenle over seng scenario / unit test cost combinaons
10% discount rate (for addional-tesng in men)
20 year me horizon (for addional-tesng in men)
CE threshold $150 / DALY averted 
(for addional tesng in men)
CE threshold $300 / DALY averted 
(for addional tesng in men)
Addional-tesng (beyond core-tesng) only in women
Addional-tesng (beyond core-tesng) only in men
Percent of HIV diagnosed people with VL < 1000  
73% to 83%**
Percent of HIV diagnosed people with VL < 1000  
46% to 66%**
Probability of HIV test when have HIV symptoms 
90% to 97%**
Probability of HIV test when have HIV symptoms 
30% to 89%**
HIV incidence 0.79 to 3.38/100 pyrs**
HIV incidence 0.07 to 0.51/100 pyrs**
Undiagnosed HIV prevalence  1.93% to 6.95%**
Undiagnosed HIV prevalence  0.35% to 1.22%**
Cost of HIV clinic visits and clinical care x 5
Overall (base case)
Figure 3. Maximum cost-per-diagnosis for testing beyond key groups to be cost-effective.
Variations in sensitivity analysis. *Lower/ **upper tertile of the distribution across setting scenarios in 2017. No bar in red indicates that for over
20% of setting scenario / unit test cost combinations there is no cost of testing per diagnosis at which testing is cost-effective.
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number of people on ART, compared with the number of new
positive tests in that period. This said, the effect of such over
ascertainment of new diagnoses could be less important if this
diagnosis is the one that leads the person to link to care and
start ART. Likewise, if testing programmes can demonstrate
linkage of people testing negative to effective prevention this
will likely enhance cost-effectiveness. We have not explicitly
considered that additional-testing may be based on distribut-
ing self tests. In the analyses we assume that 5% of people
will not agree to test unless they are symptomatic. If self test-
ing is more effective at being able to reach such individuals
than conventional testing, or if there are settings were the
size of this group is greater than 5%, self testing may have
some benefits that are currently not fully captured by this
analysis.
Our work has other limitations. Modelling is inevitably an
imperfect representation of reality, although we have
attempted to convey uncertainty. Future changes in ART pro-
grammes are taken into account in so far as we allow the
HIV epidemic to play out with people being put onto treat-
ment, interrupting treatment at various possible rates, expe-
riencing resistance mutations so that virologic failure occurs,
switching to second line regimens at a range of rates, etc.
However, we cannot know which other changes might occur
over the coming 50 years. As significant changes from the
assumptions occur, this analysis would need updating. In
addition, we sampled from an array of parameter distribu-
tions and then applied some filtering in order to generate a
range of setting-scenarios which appear to broadly represent
the distribution of a number of characteristics.
5 | CONCLUSIONS
For testing programmes in low-income settings in southern
Africa that implement universal eligibility for ART there is an
extremely strong relationship between the cost-per-diagnosis
and the cost-per-DALYs averted (ICER), indicating that that the
cost-per-diagnosis can be used to monitor the cost-effectiveness
of testing programmes.
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